Search

Author/Creator Zonder, Jeffrey

1. A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (NPI‐0052‐107): final study results. (26th October 2017)

Authors:
Spencer, Andrew; Harrison, Simon; Zonder, Jeffrey; Badros, Ashraf; Laubach, Jacob; Bergin, Krystal; Khot, Amit; Zimmerman, Todd; Chauhan, Dharminder; Levin, Nancy; MacLaren, Ann; Reich, Steven D.; Trikha, Mohit; Richardson, Paul
Journal:
British journal of haematology
Issue:
Volume 180:Number 1(2018)
Page Start:
41
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma. (15th February 2023)

Authors:
Derman, Benjamin A; Chari, Ajai; Zonder, Jeffrey; Major, Ajay; Stefka, Andrew T; Jiang, Ken; Karrison, Theodore; Jasielec, Jagoda; Jakubowiak, Andrzej
Journal:
European journal of haematology
Issue:
Volume 110:Number 5(2023)
Page Start:
564
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone. Issue 2 (28th December 2016)

Authors:
Muqbil, Irfana; Aboukameel, Amro; Elloul, Sivan; Carlson, Robert; Senapedis, William; Baloglu, Erkan; Kauffman, Michael; Shacham, Sharon; Bhutani, Divaya; Zonder, Jeffrey; Azmi, Asfar S.; Mohammad, Ramzi M.
Journal:
Cancer letters
Issue:
Volume 383:Issue 2(2016)
Page Start:
309
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Daratumumab proves safe and highly effective in AL amyloidosis. (25th June 2018)

Authors:
Khouri, Jack; Kin, Andrew; Thapa, Bicky; Reu, Frederic J.; Bumma, Naresh; Samaras, Christy J.; Liu, Hien D.; Karam, Mary A.; Reed, Janice; Mathur, Saveta; Faiman, Beth M.; Devries, Georgia; Zonder, Jeffrey; Valent, Jason
Journal:
British journal of haematology
Issue:
Volume 185:Number 2(2019)
Page Start:
342
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. (August 2019)

Authors:
Hari, Parameswaran; Paba-Prada, Claudia E.; Voorhees, Peter M.; Frye, John; Chang, Yu-Lin; Moreau, Philippe; Zonder, Jeffrey; Boccia, Ralph; Shain, Kenneth H.
Journal:
Leukemia research
Issue:
Volume 83(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study. Issue 12 (December 2015)

Authors:
Richardson, Paul G; Jagannath, Sundar; Moreau, Philippe; Jakubowiak, Andrzej J; Raab, Marc S; Facon, Thierry; Vij, Ravi; White, Darrell; Reece, Donna E; Benboubker, Lotfi; Zonder, Jeffrey; Tsao, L Claire; Anderson, Kenneth C; Bleickardt, Eric; Singhal, Anil K; Lonial, Sagar
Journal:
Lancet
Issue:
Volume 2:Issue 12(2015)
Page Start:
e516
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗